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Strengths and limitations of this study
 ► It is evident that time- driven activity- based costing 
(TDABC) is a valid and practical method for assess-
ing costs of treatment pathways in breast cancer.
 ► This study illustrates that TDABC is flexible towards 
the classification, length and design of treatment 
pathways.
 ► This study shows that an adequate level of cost 
transparency can already be obtained with a mini-
mum set of data.
 ► The study’s focus is costs only and not linked to 
treatment outcome.
 ► This study does not allow one to empirically quantify 
the impact of characteristics on treatment costs.
AbStrACt
Objectives Using a standardised diagnostic and generic 
treatment path for breast cancer, and the molecular 
subtype perspective, we aim to measure the impact 
of several patient and disease characteristics on the 
overall treatment cost for patients. Additionally, we aim to 
generate insights into the drivers of cost variability within 
one medical domain.
Design, setting and participants We conducted a 
retrospective study at a breast clinic in Belgium. We 
used 14 anonymous patient files for conducting our 
analysis.
results Significant cost variations within each 
molecular subtype and across molecular subtypes 
were found. For the luminal A classification, the cost 
differential amounts to roughly 166%, with the greatest 
treatment cost amounting to US$29 780 relative to 
US$11 208 for a patient requiring fewer medical 
activities. The major driver for these cost variations 
relates to disease characteristics. For the luminal B 
classification, a cost difference of roughly 242% exists 
due to both disease- related and patient- related factors. 
The average treatment cost for triple negative patients 
amounted to US$26 923, this is considered to be a more 
aggressive type of cancer. The overall cost for HER2- 
enriched is driven by the inclusion of Herceptin, thus 
this subtype is impacted by disease characteristics. Cost 
variability across molecular classifications is impacted 
by the severity of the disease, thus disease- related 
factors are the major drivers of cost.
Conclusions Given the cost challenge in healthcare, the 
need for greater cost transparency has become imperative. 
Through our analysis, we generate initial insights into 
the drivers of cost variability for breast cancer. We found 
evidence that disease characteristics such as severity and 
more aggressive cancer forms such as HER2- enriched 
and triple negative have a significant impact on treatment 
cost across the different subtypes. Similarly, patient factors 
such as age and presence of gene mutation contribute to 
differences in treatment cost variability within molecular 
subtypes.
IntrODuCtIOn
The aim of this study is to analyse the vari-
ability in treatment costs for a single disease 
using the perspective of molecular subtypes 
and several patient- specific and disease- 
specific characteristics. Worldwide, it has 
been documented that healthcare costs 
are on the rise.1 This increase is driven by a 
number of factors related to ageing popula-
tion, technological advancements and the 
current reimbursement system.2 3 However, 
in conjunction with these factors it has been 
noted that significant cost variation exists 
across hospitals in providing care.4 To curb 
higher expenditure and reduce cost vari-
ability, greater understanding of the drivers 
of variation is warranted.5 Using time- driven 
activity- based costing (TDABC), we aim to 
quantify the impact of multiple characteris-
tics on the overall cost of treatment. Previous 
academic studies have drawn attention to 
identifying particular variables that lead to 
differences in costs for hospitals.6–10 These 
studies provide evidence that costs can vary 
based on a number of factors such as hospital 
structure and physician variables.
We focus on breast cancer as the medical 
disease to examine the impact of patient and 
disease factors on the variability of costs. Glob-
ally, breast cancer remains the most commonly 
diagnosed cancer and it is the leading cause 
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of death in women.11 Breast cancer is considered a 
heterogeneous disease, and evidence shows that clinically 
similar tumours often translate into different prognoses 
and react differently to therapy.12 From existing medical 
literature, we see that patient and disease characteristics 
play a significant role in the treatment path followed by 
patients.13 The classification of the disease is based on 
severity, and patients’ overall health status impacts the 
medical decisions taken.14 Using the four main molec-
ular subtypes of breast cancer, we aim to quantify the 
impact of these characteristics on the variability of costs. 
Our academic study takes place in the breast clinic of 
a hospital where all patients are treated by a multidis-
ciplinary team (MDT). The MDT is responsible for all 
medical decisions, and patients are surgically treated by 
the same oncoplastic surgeon, therefore controlling for 
hospital and physician variability. To accurately measure 
costs we use TDABC as the costing technique, which has 
been proposed by Kaplan and Anderson15 and has been 
used in a growing body of research.16 17
MethODS
Overall tDAbC model
Our research was conducted at a breast clinic located 
in Belgium. All relevant patient and financial data were 
collected through a research collaboration with a general 
hospital. Through face- to- face interviews with the physi-
cian and medical staff, generic process maps for each step 
in the intervention path were developed.18 A full overview 
of the treatment steps can be found in online supplemen-
tary appendix A. Through designing the process maps, 
the relevant activities were identified with the corre-
sponding medical personnel, medical equipment and 
facilities used. Time estimates were based on the average 
time spent per activity, and the full duration of the activity 
was covered. The estimates used are based on subjective 
estimates provided by the medical personnel. All data 
were collected through interviews with medical staff and 
through direct observations.
Annual costs for medical equipment and hospital facil-
ities were retrieved from the financial database of the 
hospital in collaboration with the finance department. 
All costs used in our analysis are taken from the perspec-
tive of the hospital. Salaries include all additional remu-
neration benefits paid to employees. Given the sensitivity 
surrounding remuneration, the cost for medical 
personnel was calculated using figures from a Belgian 
study published by the Belgian Health Care Knowledge 
Centre in 201219 which is a federal research institution 
focusing on healthcare research. To provide a more accu-
rate salary figure, an index of 7.2% was added to account 
for inflation.
Costs relating to the surgical intervention were made 
up of medical personnel’s salaries, direct medical mate-
rials, medical machines and equipment and indirect 
costs. For our study, we worked with one breast surgeon 
who works in a standardised way. We had one dedicated 
operating team made up of one nurse, a surgical trainee 
and anaesthetist for all surgical interventions, thus we 
limit any potential variability that may arise from the use 
of different surgical techniques. Through direct obser-
vation of the surgical procedures, full lists were made 
regarding all the medical instruments used in each type 
of surgical intervention. The per unit cost of the direct 
medical materials was provided by the pharmaceutical 
department of the hospital. These costs represent the 
direct cost the hospital pays to their suppliers for these 
materials.
For all medical machines and equipment, the annual 
cost was made up of the maintenance and depreciation 
costs for a year. Facilities costs were incorporated into the 
indirect costs of the departments. The full indirect costs 
covered depreciation and maintenance costs, financial 
and general costs, heating, administrations, linen, food, 
personnel accommodation and other medical costs.
The annual practical capacity was calculated for all 
resources. The practical capacity used within the hospital 
for in- house medical staff amounts to 1620 hours/year/
person. This amount takes into account all potential vaca-
tion days, clinical days and other administrative breaks. 
The practical capacity for the medical machines is based 
on the same available number of hours as in- house 
medical staff. The more senior medical staff employed 
as independents have a practical capacity of 2400 hours/
year/person. The cost per unit of resources used is 
displayed in online supplementary appendix B.
Patient and disease characteristics
Using the general treatment framework, we consulted 
medical literature and identified several relevant patient 
and disease characteristics to analyse how these factors 
impact the costs through their impact on the treatment 
path. A full overview of the selected patient and disease 
factors for this analysis is displayed in table 1.20–22 Each 
treatment step was impacted by the presence of one or 
more of the listed characteristics. Our analysis focuses on 
how these factors drive cost differences for patients within 
and between molecular classifications.
Based on medical guidelines, the starting point for all 
breast cancer patients is the standard diagnostic process 
made up of the triple assessment.23 This allows physicians 
to confirm the diagnosis and to assess the tumour biology 
to define the molecular subtype. Historically, clinicopath-
ological parameters such as tumour size, lymph node 
involvement and histological grade were used to diag-
nose breast cancer patients.24 However, the advancement 
of technology has allowed for greater understanding of 
the molecular biology of the disease. Biomarkers such 
as Ki-67 proliferation index, estrogen receptor (ER), 
progesterone receptor (PR) and epidermal growth factor 
receptor 2 (HER2) are used to classify patients into 
molecular subtypes.25 Several molecular subtypes have 
been developed using these biomarkers. We focused on 
the four main subtypes, namely luminal A and B, triple 
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negative and HER2- enriched and use these groupings to 
stage patients.
Patients classified as luminal A display positive expres-
sions for ER and PR, with the absence of HER2, and have 
low proliferation and histological grades.20 In compar-
ison, luminal B subtypes express lower levels for hormonal 
receptors (ER and PR) but could express positive levels 
for HER2.
Luminal B classifications are more aggressive due to 
their higher histological grade and proliferation levels.20 26 
HER2- enriched cancer displays an overexpression for the 
HER2 gene pathway,12 and the majority of cases express 
low levels of hormonal genes.27 HER2- enriched cancers 
have high proliferation levels and grade.26 The triple 
negative subtype displays low expressions for all three 
important receptors, namely ER, PR and HER2, and high 
grade and proliferation are associated with triple negative 
tumours.28
Based on the molecular subtype and other classical 
disease parameters, the MDT determines the possible 
need for neoadjuvant therapy before surgery. Having 
completed the diagnostic workout and any necessary 
neoadjuvant therapy, patients are then expected to 
undergo a surgery intervention compromising of either 
breast conservative surgery (BCS) or mastectomy (MX). 
This decision is largely driven by the severity of the disease 
and in some cases by patient characteristics pertaining to 
the presence of oncogenetics. Additional interventions 
are conducted during the surgery such as the sentinel 
node procedure and the axillary dissection. Inclusion 
of these measures are driven by positive results of the 
biopsy testing during surgery. Following surgery, local 
adjuvant therapy is then administered in the form of radi-
ation therapy. The MDT determines the systemic treat-
ment such as adjuvant chemotherapy, adjuvant hormonal 
therapy and adjuvant Herceptin. The combination of 
adjuvant therapy is driven by the molecular subtype of 
the disease as well as the patient and disease characteris-
tics, such as age of patient at diagnosis and higher tumour 
grade and size.
The time frame used in our generic treatment path-
ways varied depending on the inclusion of neoadjuvant 
therapy, the inclusion of local adjuvant radiation therapy 
and the type of systemic therapy chosen for the patient. 
On average the diagnostic workup was performed over 
a maximum of 2 weeks, including the MRI scan. The 
surgical intervention was performed 1 week after the 
full diagnostic workup was complete, unless neoadjuvant 
treatment was required. For neoadjuvant and adjuvant 
Herceptin therapy, the costs represent the 18 sessions 
required resulting in an administration timeline of 12 
months. For neoadjuvant and adjuvant chemotherapy, the 
full costing was used for all required sessions which typi-
cally lasts 6 months. The costs for local adjuvant radiation 
therapy represent the 4–5 weeks standard time period. 
Based on medical guidelines, regarding the administra-
tion of adjuvant hormonal therapy, costs were calculated 
on either 5–10 years, and this information was provided 
in the patient files. The cost for endocrine therapy has 
been included in the adjuvant hormonal therapy amount. 
For the purpose of our analysis we excluded ovarian 
suppression costs, and we acknowledge that the inclusion 
of this activity for premenopausal patients will increase 
treatment costs as this can either be achieved through 
a surgical intervention or the administration of GnRH 
analogues. However, this intervention is required only 
for a subpopulation of patients; therefore, they were not 
included in our study.
For our analysis, we used a total of 14 patient files to 
illustrate the effect of several characteristics identified on 
the generic treatment path and how those subsequently 
impacted the overall treatment costs for patients. Our 
reasoning for selecting these 14 patients was to capture 
a diverse number of characteristics. The selected patients 
not only had different characteristics across the four 
molecular subgroups but they also had differences within 
the molecular classifications. We excluded patients with 
extreme comorbidities from our analysis. The presence 
of comorbidities impacts the decision- making regarding 
the treatment pathway patients follow and subsequently 
impacts costs. However, the intersection between severe 
comorbidities and breast cancer fell beyond the scope of 
our research. The full treatment cost for each patient was 
calculated based on the medical interventions and the 
per unit cost calculated using the TDABC technique. An 
overview of the patient files and the relevant characteris-
tics of the patients can be found in table 2.
Patient and public involvement
Patients had no influence on the research questions or 
outcomes of this research. No patients were involved in 
the design of this study. We used blind patient files; there-
fore, no patient recruitment took place. We included only 
certain patient and disease characteristics which were 
made available to us by the physician, and no personal 
information of patients was used in this study. Given the 
nature of removing all personal information, there is no 
requirement to disseminate the information to patients.
reSultS
From the costing results, we identified that a signifi-
cant variation in treatment costs exists between patients 
within each molecular subtype as well as across molec-
ular subtypes. Typically for luminal A the cost differential 
amounts to roughly 166%, and the greatest treatment 
cost amounts to US$29 780 relative to US$11 208 for 
a patient requiring fewer medical activities. The major 
driver of cost is due to disease- specific characteristics 
such as the higher tumour grade, tumour size and the 
presence of extensive lymph node involvement. These 
characteristics may lead to the inclusion of adjuvant 
chemotherapy as part of the treatment. When focusing 
our attention on luminal B, we noticed that patients 
with identical disease characteristics, such as tumour 
size and grade, resulted in the same overall treatment 
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costs, amounting to US$16 335. However, the treatment 
costs tend to increase exponentially when the disease 
characteristics are higher or considered to be more 
aggressive. Additionally, patient- related factors lead 
to cost variations for luminal B. We noted that age at 
diagnosis, particularly patients aged 40 and below, and 
the presence of oncogenetic factors tend to have higher 
overall treatment costs due to more aggressive treatment 
schemes that include neoadjuvant therapy and a combi-
nation of surgery interventions and adjuvant therapy. 
These disease and patient characteristics resulted in a 
242% cost difference whereby treatment costs ranged 
from US$13 435 to US$45 908.
Historically, the triple negative subtype is considered to 
be a highly aggressive form of cancer. Therefore, costs for 
this particular subtype are driven by disease characteris-
tics. Based on medical guidelines, neoadjuvant therapy is 
recommended for this subtype before surgery. Taking this 
into consideration, the average treatment cost amounts 
to US$26 923. The final subtype, HER2- enriched, on 
average has the highest overall treatment cost due to the 
inclusion of Herceptin as part of the treatment inter-
vention. Therefore, the characteristics of the disease 
pertaining to receptor status play an important driver 
of cost for this subtype. HER2- enriched cancer requires 
treatment against the HER2 receptor. Additionally, like 
luminal B, the positive presence of oncogenetics and the 
age below 40 years impact the cost through the inclusion 
of neoadjuvant therapy and more aggressive adjuvant 
therapy schemes.
When considering the costs variability across the 
molecular subtypes, we notice that the more aggressive 
classifications like triple negative and HER2- enriched 
are driven by the disease characteristics. The medical 
decision- making is heavily influenced by the need to 
contain the growth of the cancer in the patient. Conse-
quently, the medical interventions needed to treat these 
types of cancers are more detailed, such as incorporating 
neoadjuvant therapy into the treatment path, thus by 
definition leading to cost differences across the classifica-
tions. A similar remark can be made about luminal A type 
cancers that are impacted by the disease characteristics. 
However, the major motive for costs differences between 
luminal A, triple negative and HER2- enriched relate to 
the fact that luminal A type cancer is often considered to 
be less aggressive. The number of medical interventions 
required is considerably fewer for luminal A. From our 
analysis, most luminal A patients did not require exten-
sive adjuvant therapy that generally impacts overall cost. 
We noted that luminal B is the most complex classifica-
tion in that the medical decisions taken for this group 
can be impacted by both patient and disease- related 
variables. These equally serve as drivers of cost unlike 
the other three classifications that are largely impacted 
by disease characteristics only. The full treatment costs 
covering all the relevant activities for the 14 patients can 
be found in table 3.
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DISCuSSIOn
Given the consistent global rise in healthcare costs, an 
increased need for understanding cost variability and 
greater cost transparency has been initiated.2 Significant 
value exists when a higher knowledge of cost variability 
is obtained. Hospitals and management are in a better 
position to anticipate future spending, make more accu-
rate spending forecasts and make adjustments to their 
planning and processes.29 Additionally, understanding 
cost fluctuations allows for better measurement of ineffi-
ciencies and potentially provides solutions for the current 
reimbursement system.4 In the current state of the sector, 
little is known about the true cost of treatment for most 
diseases. Consequently, this lack of knowledge hampers 
the efforts positioned towards cost reduction and reim-
bursement changes. Through our analysis, we focus on 
understanding how treatment costs vary as a result of 
several patient and disease characteristics. This perspec-
tive enables medical providers and physicians to predict 
the potential costs of treatment upfront, which is not 
currently being done.30
When shifting our focus onto the particular molec-
ular subtypes, we are able to identify specific character-
istics contributing to the fluctuations in treatment costs. 
When looking at the luminal A subgroup, we noticed 
that disease characteristics impacted the treatment 
path decision. Luminal A breast cancer is considered 
to have a less aggressive tumour biology, in comparison 
with the other molecular subtypes, and has a better 
prognosis. However, when looking at the patient files 
we noticed that even within luminal A some patients 
may have more aggressive cancers. For this particular 
subgroup, the major driver for decision- making boils 
down to the characteristics of the disease. Two patients 
with similar age and patient- related factors have major 
cost variability. We noted that higher tumour grade, a 
larger tumour size and the presence of extensive nodal 
involvement may require the inclusion of adjuvant 
chemotherapy for treatment, as higher levels of these 
factors imply that patients are at greater risk.31
For the luminal B subtype, both patient and disease- 
related factors could potentially play a role on cost vari-
ation. In the one instance, patients F and G had vastly 
similar disease- specific characteristics such as tumour 
grade, tumour size and nodal status, thus requiring 
identical treatment interventions resulting in treatment 
costs totalling roughly US$16 335. Patients H and I had 
comparable disease characteristics but major differ-
ences related to patient characteristics. Patient I was 
below the age of 40 at the time of diagnosis and tested 
positive for both the HER2 receptor and the BRC2 
mutation gene. The presence of BRC2 potentially trans-
lates into an increased chance of locoregional relapse 
and/or an increase of contralateral breast cancer. 
These specific patient factors may lead to the inclusion 
of neoadjuvant therapy (chemotherapy and Herceptin) 
and may influence the type of surgery, in some cases, 
with or without prophylactic MX instead of BCS. The 
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inclusion of neoadjuvant and adjuvant therapy poten-
tially increases the overall treatment price by approxi-
mately US$34 000.
Both HER2- enriched and triple negative are classified 
as more aggressive types of cancer. The total costs are 
largely driven by the increased combination of inter-
ventions needed. The tumour grade and proliferation 
index for these subtypes are generally higher. Given 
the name, HER2- enriched patients test positive for the 
HER2 receptor, requiring either neoadjuvant Herceptin 
therapy or adjuvant Herceptin therapy. The inclusion 
of Herceptin into the proposed treatment plan has a 
dramatic increase in the total costing. The full admin-
istration of Herceptin increases the treatment cost by 
approximately US$16 403 per patient. Therefore, this 
particular molecular subtype carries an enormous cost 
burden.
In comparison, triple negative subtypes display nega-
tive expression for all receptors. However, both patient 
characteristics like age and disease characteristics 
impact the cost based on the treatment decision. High 
tumour grades and high proliferation grades require 
more aggressive interventions increasing the cost 
through the need for treatment regimens which include 
chemotherapy. The full costing for chemotherapy per 
patient averages around US$16 415. For the triple nega-
tive patient, the inclusion of adjuvant chemotherapy is 
driven by the high proliferation levels and the grade of 
the tumour requiring more aggressive treatment.
When shifting our focus to other academic studies, 
we find one study within breast cancer which has calcu-
lated and analysed costs of a particular treatment step, 
like the radiation therapy, in the entire treatment 
process.17 Some studies have used conventional breast 
cancer staging to calculate costs for each stage using the 
average cost in hospitals.32 Additionally, specific medical 
studies have looked at linking molecular classifications 
to the prognosis of cancer.33 Other studies focusing on 
cost variability have focused mainly on hospital- related 
characteristics and the impact on average costs. These 
studies found that characteristics such as the type of 
hospital structure (public vs private), the level of inno-
vation and medical technology in the institution, the 
case load of surgeons and discharge dispositions influ-
ence costs.6–9
As part of the value era one of the key reform initia-
tives to depart from the current fee- for- service reim-
bursement system is the introduction of bundled 
payments, whereby the full episode of care is financed. 
The initiation of bundled payments highlights the need 
for healthcare providers to predict which patients are at 
risk of higher treatment costs for a disease.34 To achieve 
this, we have to turn our attention to the factors that 
drive variability. We provide initial insights into the 
average treatment costs for the molecular subtypes high-
lighting the cost impact of several disease and patient 
characteristics on the treatment pathway. By shifting 
the focus to analysing costs through the perspective 
of molecular subtypes and identifying the impact of 
several characteristics on cost, we aim to provide an 
alternative perspective into the way bundled payments 
could potentially be introduced.
In addition to generating an alternative approach for 
dealing with the change in the reimbursement system, 
we believe that this method could form the basis for 
other medical domains for future academic research. 
We chose to analyse patient and disease characteristics 
within early- stage breast cancer because of the disease’s 
standardised nature. All patients undergo triple assess-
ments for diagnosing, followed by a generic neoadju-
vant and adjuvant treatment pathway. However, we 
recognise that the perspective of understanding cost 
variability could be applied to other disease domains. 
Insights could be generated in disease areas which 
follow a standard diagnosing path, ones with minor 
surgical intervention and a generic treatment path 
postsurgery. An alternative oncological domain that 
could potentially be interesting to explore would be 
colon cancer that has standardised biopsy interven-
tions. The field of dermatology serves as an interesting 
non- oncological domain as the treatment pathology 
is highly standardised for patients. Additionally, other 
medical domains that follow a similar disease classifica-
tion like the molecular subtypes found in breast cancer 
serve as another interesting medical disease to which 
this approach could potentially be applied.
Using the generic treatment pathway developed, 
we provide evidence that significant cost variability 
exists across molecular subtypes and within molecular 
subtypes. We provide evidence that patient and disease- 
related factors impact the treatment path and high-
light the impact on costs. However, one limitation of 
our study relates to the fact that limited generalisations 
can be made given the limited patient data used. For 
the purpose of our analysis, we selected 14 patient files 
to provide initial results that cost variability does exist 
as a result of patient and disease characteristics within 
the molecular subtypes. We believe that an extension 
to our research could focus on understanding how and 
to what extent these characteristics drive or impact cost 
variability through an empirical analysis using a larger 
sample size. Furthermore, a larger sample size allows 
one to explore the statistical impact of several charac-
teristics on driving cost differences. This serves as an 
interesting avenue for research focusing on under-
standing cost variability in disease settings.
Another potential extension of this research is to 
link costs to the quality of care provided to generate 
insights into cost- effectiveness. With the push towards 
a value system, studies that focus on both costs and 
outcomes have become imperative. With the limitation 
surrounding the availability of quality data, we were 
unable to provide relevant academic findings for how 
this alternative perspective could impact the outcomes 
achieved for treating patients with breast cancer. There-
fore, we recognise a need for future research that 
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focuses on costs and their link to quality. By looking 
at costs and the impact costs have on quality, we move 
into a realm of being able to provide insights into cost- 
effectiveness strategies.
In conclusion, specific patient and disease characteris-
tics play a major role in the treatment interventions and 
pathway for patients. Each molecular subtype is impacted 
by the range of patient and disease- related factors. These 
factors impact the overall cost of treatment within the 
four major molecular subtypes as well as across the 
molecular subtypes. Significant cost differences exist 
across the subtypes due to the severity of the disease, 
more aggressive forms such as HER2- enriched and triple 
negative require increased medical interventions leading 
to higher overall costs. Cost differences within molecular 
subtypes are driven in part by disease characteristics, 
but also heavily influenced by patient factors. By using 
the medical focus of the disease and linking it to costs 
and understanding the drivers of cost, we move one step 
closer to making more sound cost reduction decisions.
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